Surgery for Liver Metastases of Colorectal Etiology in Czech Republic: Current National Survey

Česká verzia

Authors: M. Ryska ¹; J. Pantoflíček ¹; L. Dušek ²
Authors place of work: Univerzita Karlova, 2. LF UK a ÚVN Praha, Chirurgická klinika, přednosta: prof. MUDr. Miroslav Ryska, CSc. ¹; Ústav biostatistiky a analýz, Přírodovědecká a Lékařská fakulta, MU Brno ředitel: doc. RNDr. Ladislav Dušek, Ph. D. ²
Published in the journal: Rozhl. Chir., 2010, roč. 89, č. 2, s. 100-108.
Category: Monothematic special - Original

Summary

Background:
Czech Republic is the first in the incidence of colorectal carcinoma (CRC) in all over the world. There is 60% development of liver metastases in the patients with colorectal carcinoma (LMCRC). Liver resection as the most effective therapeutic choice potentially curative is available only in 20% of the patients with CRC. Surgery with adjuvant chemotherapy leads to 5yr. survival in 50% of patients with LMCRC.

Aim of study:
To evaluate how many patients with LMCRC are indicated for liver surgery and how many patients are predicted for surgery every year in Czech Republic.

Methods:
A questionnaire was sent to 140 surgical department of Czech Republic in 2001, 142 in 2009 respectively with questions regarding to surgical treatment of LMCRC. The data were compared to similar survey evaluation on The Netherlands and Austria and data from Czech national oncology registry.

Results:
217 liver resection (57 major including) resp. 466 (140 major including) were done in Czech Republic in 2000, resp. 2008 (114.7% growth). Number of liver resections providing in 2000 resp. 2008 compared to predictive number of liver surgery was 24.1%, resp. 49.4% (approx. 100% growth). Number of liver resections for primary as well for secondary malignancy in Czech national oncology registry was involved together.

Conclusion:
High incidence of CRC leads to high incidence of LMCRC in Czech Republic. About 1.000 patients with LMCRC can be expected in Czech Republic in the 60% development of LMCRC and 20% resectability every year. Only 50% of patients with LMCRC have the chance for adequate therapy nowadays. For the evaluation of quality of surgical department other studies are needed.

Key words:
colorectal cancer – liver – metastases – resection – questionnaire

Zdroje

1. Zavoral, M., Suchanek, S., Zavada, F. et al. Colorectal cancer screening in Europe. World J. Gastroenterol., 2009; 15: 5907–5915.

2. Dušek, L., Mužík, J., Kubásek, M., Koptíková, J., Žaloudík, J., Vyzula, R. Epidemiologie zhoubných nádorů v České republice [online]. Dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802 – 8861

3. Scheele, J., Stang, R., Altendorf-Hofmann, A., et al. Resection of colorectal liver metastases. World J. Surg., 1995; 19: 59–71.

4. Sasaki, A., Iwashita, Y., Shibata, K., et al. Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastase of colorectal carcinoma. S Gastrointest. Surg., 2005; 9: 374–380.

5. Adam, R., Lucidi, V., Bismuth, H. Hepatic colorectal metastases: methods of improving resectability. Surg. Clin. North Am., 2004; 84: 659–671.

6. van Gulik, T. M., van den Esschert, J. W., de Graf, W., et al. Controversies in the use of portal vein embolisation. Dig. Surg., 2008; 25: 436–444.

7. Kaczirek, K., Tamandl, D., Kliner, M., et al. Criteria for resectability of colorectal cancer liver mestatases – an Austrian survey and current recommendations. Eur. Surg., 2009; 41/5: 213–220.

8. Mulier, S., Ruers, T., Jamart, J., et al. RFA versus resection for resectable colorectal liver metastase: time for a randomized trial? Dig. Surg., 2008; 25: 445–460.

9. Bipat, S., van Leeuwen, M. S., Ijzermans, J. N. M., et al. Evidence.based guideline on management of colorectal liver metastase in the Netherlands. Neth. J. Med., 2007; 65: 5–14.

10. Welsh, F. K. S., Tekkis, P. P., John, T. G., et al. Predictive models in colorectal liver metastase – can we personalize treatment and outcome? Dig. Surg., 2008; 25: 406–412.

11. Pantoflíček, J., Ryska, M., Bělina, F. Léčba jaterních metastáz kolorektálního původu v České republice. Výsledky celostátní dotazníkové akce. Bull. HPB, 10, 2002: 147–150.

12. van de Velde, C. H. J., de Braun, L. M. Attitudes towards detection and management of hepatic metastase in the western world. Eur. J. Cancer Clin. Oncol., 1988; 24: 791–794.

13. Bruinvels, D. J., de Braun, L. M., Kievit, J., et al. Attitudes towards detection and management of hepatic metastase of colorectal origin: a sekond look. HPB Surgery, 1994; 8: 115–122.

14. Pawlik, T. M., Schulick, R. D., Choti, M. A. Expanding criteria for resectability of colorectal liver metastases. Oncologist, 2008; 13: 51–64.

15. Scarborough, J. E., Pietrobon, R., Clary, B. M., et al. Regionalization of hepatic resections is associated with increasing disparities among some patient populations in use of high-volume providers. J. Am. Coll. Surg., 2008; 207: 831–838.

16. Evans, J. Ablative and catheter – delivered therapies for colorectal liver metastases (CRLM). Eur. J. Surg. Oncol., 2007; 33: Suppl 2: S64–75.

17. Bipat, S., van Leeuwen, M. S., Ijzermans, J. N. M., et al. Imaging and treatment of patiens with colorectal liver metastase in the Netherlands: a survey. The Nether. J. Med., 2006; 64: 147–151.

18. Mulier, S., Ruers, T., Jamart, J., et al. RFA versus resection for resectable colorectal metastase: time for a randomized trial? Dig. Surg., 2008; 25: 4445–4460.

19. Malik, H. Z., Hamady, Z. Z., Adair, R., et al. Prognostic influence of multiple hepatic metastase from colorectal cancer. Eur. J. Surg. Oncol., 2007; 33: 468–473.

20. Choti, M. A., Sitzmann, J. V., Tiburi, M. F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastase. Ann. Surg., 2002; 235: 759–766.

21. van Cutsem, E., Nordlinger, B., Adam, R., et al. Towards a pan-European consensus on the treatment of patiens with colorectal liver metastase. Eur. J. Cancer, 2006; 42: 2212–2221.

22. Knodell, R. G., Ishak, K. G., Black, W. C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981; 1: 431–435.

23. Belghiti, J., Ogava, S. Assessment of hepatic reserve for the indication of hepatic resection. J. Hepatobiliary Pancreat. Surg., 2005; 12: 1–3.

24. Abulkhir, A., Limongelli, P., Healey, A. J., et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann. Surg., 2008; 247: 49–57.

25. Carpizo, D. R., D’Angelica, A. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol., 2009; 10: 801–809.

26. Třeška, V., Skalický, T., Sutnar, A., et al. Chirurgická léčba jaterních metastáz kolorektálního karcinomu. Rozhl. Chir., 2009; 88: 69–74.

27. Ryska, M., Bělina, F., Langer, D., et al. Výsledky radikální chirurgické léčby u nemocných s jaterními metastázami kolorektálního karcinomu. Rozhl. Chir., 2010; 89: v tisku.